title: Sub-acute toxicity profile of a modified resveratrol supplement.
abstract: Longevinex, a nutraceutical formulation containing Resveratrol as the main component along with other polyphenolics exhibits diverse health benefits but systemic safety studies are lacking. Hence, to test the safety of Longevinex use for therapeutic purposes, 50 Sprague Dawley rats were randomly divided into five groups (n=10; 5M, 5F) wherein group I as vehicle treated control, group II and group III received 50 mg and 100 mg of plain Resveratrol respectively and group IV and group V received 50 mg and 100 mg of Longevinex respectively for a period of 28 days. All toxicological parameters were analyzed as per OECD-407 guidelines. Results showed treatment with Resveratrol and Longevinex did not result in any mortality of rats neither did they exhibit any clinical signs of toxicity. Hematological and biochemical analysis of serum enzymes and metabolites were not significantly altered between Longevinex and control rats. Likewise, histopathological analysis for various organs did not reveal significant changes in the vital organs of the treated rats. The study revealed that there were no significant treatment related adverse effects in rats exposed to Longevinex for 28 days and considered safe at the given dose where compared to plain Resveratrol.
authors.affiliation: Department of Biotechnology, School of Life Sciences, Pondicherry University, Puducherry, India.
authors.forename: M K
authors.initials: MK
authors.lastname: Sangeetha
authors.forename: D Eazhisai
authors.initials: DE
authors.lastname: Vallabi
authors.forename: Veeresh Kumar
authors.initials: VK
authors.lastname: Sali
authors.forename: J
authors.initials: J
authors.lastname: Thanka
authors.forename: Hannah R
authors.initials: HR
authors.lastname: Vasanthi
mesh_terms: D000818:Animals; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry; D000975:Antioxidants / Q000008:administration & dosage / Q000009:adverse effects* / Q000737:chemistry; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry; D003373:Coumaric Acids / Q000008:administration & dosage / Q000009:adverse effects* / Q000737:chemistry; D019587:Dietary Supplements / Q000009:adverse effects* / Q000032:analysis; D005260:Female; D008297:Male; D019055:No-Observed-Adverse-Effect Level; D010833:Phytic Acid / Q000008:administration & dosage / Q000009:adverse effects* / Q000737:chemistry; D011794:Quercetin / Q000008:administration & dosage / Q000009:adverse effects* / Q000737:chemistry; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage / Q000009:adverse effects* / Q000737:chemistry; D059551:Toxicity Tests, Subacute
chemical_list: D000924:Anticholesteremic Agents; D000975:Antioxidants; D002316:Cardiotonic Agents; D003373:Coumaric Acids; D013267:Stilbenes; D010833:Phytic Acid; D011794:Quercetin; C004999:ferulic acid; D000077185:Resveratrol
keywords: ACP; ALP; Acid Phosphatase; Alkaline Phosphatase; Clinical biochemistry; DMSO; Dimethylsulfoxide; EDTA; Ethylenediaminetetraacetic acid; GGT; H&E; HGB; Hematology; Hematoxylin and eosin; Hemoglobin; LDH; Lactate Dehydrogenase; Longevinex; NOAEL; No observed adverse effect level; Resveratrol; SD; SEM; SGOT; SGPT; Serum Glutamic Oxaloacetic Transaminase; Serum Glutamic Pyruvic Transaminase; Sprague Dawley rats; Standard error means; Sub-acute toxicity; ULN; Upper Limit of Normal; γ-Glutamyltransferase